Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KALV Stock Forecast 2025-2026
$11.42
Current Price
$593.60M
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KALV Price Targets
+241.5%
To High Target of $39.00
+145.2%
To Median Target of $28.00
+57.6%
To Low Target of $18.00
KALV Price Momentum
-4.3%
1 Week Change
-8.3%
1 Month Change
+1.2%
1 Year Change
+34.8%
Year-to-Date Change
-26.3%
From 52W High of $15.50
+56.4%
From 52W Low of $7.30
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching KalVista (KALV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on KALV and similar high-potential opportunities.
Latest KALV Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, KALV has a bullish consensus with a median price target of $28.00 (ranging from $18.00 to $39.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $11.42, the median forecast implies a 145.2% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Schwartz at SVB Leerink, projecting a 241.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KALV Analyst Ratings
10
Buy
0
Hold
0
Sell
KALV Price Target Range
Low
$18.00
Average
$28.00
High
$39.00
Current: $11.42
Latest KALV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KALV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $28.00 |
| Mar 26, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Maintains | $30.00 |
| Mar 26, 2025 | Needham | Serge Belanger | Buy | Reiterates | $28.00 |
| Mar 26, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $19.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $20.00 |
| Mar 13, 2025 | Needham | Serge Belanger | Buy | Reiterates | $28.00 |
| Mar 3, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $19.00 |
| Jan 31, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Initiates | $19.00 |
| Jan 7, 2025 | TD Cowen | Stacy Ku | Buy | Initiates | $30.00 |
| Dec 18, 2024 | B of A Securities | Tazeen Ahmad | Buy | Initiates | $22.00 |
| Dec 9, 2024 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $0.00 |
| Dec 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $20.00 |
| Dec 5, 2024 | Needham | Serge Belanger | Buy | Reiterates | $28.00 |
| Oct 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $20.00 |
| Sep 27, 2024 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $35.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $20.00 |
| Sep 6, 2024 | Needham | Serge Belanger | Buy | Reiterates | $32.00 |
| Jul 15, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $20.00 |
| Jul 12, 2024 | Needham | Serge Belanger | Buy | Maintains | $32.00 |
KalVista Pharmaceuticals Inc. (KALV) Competitors
The following stocks are similar to KalVista based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
KalVista Pharmaceuticals Inc. (KALV) Financial Data
KalVista Pharmaceuticals Inc. has a market capitalization of $593.60M with a P/E ratio of -3.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -150.5%.
Valuation Metrics
Market Cap
$593.60M
Enterprise Value
$342.70M
P/E Ratio
-3.3x
PEG Ratio
-6.4x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+44.6%
Current Ratio
10.4x
Debt/Equity
4.0x
ROE
-150.5%
ROA
-58.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
KalVista Pharmaceuticals Inc. (KALV) Business Model
About KalVista Pharmaceuticals Inc.
What They Do
Develops small molecule protease inhibitors for diseases.
Business Model
KalVista Pharmaceuticals operates as a clinical-stage pharmaceutical company, focusing on discovering and developing treatments for diseases with significant unmet medical needs. The company generates revenue through the advancement of its drug candidates, particularly in the niche market of hereditary angioedema, and potentially from future commercialization of its innovative therapies.
Additional Information
KalVista is based in Cambridge, UK, and has operations in the United States. Its research includes developing oral treatments for diabetic eye disease, which could potentially transform standard care practices. The company's unique approach to rare diseases positions it as a significant player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
150
CEO
Mr. Benjamin L. Palleiko
Country
United States
IPO Year
2015
Website
www.kalvista.comKalVista Pharmaceuticals Inc. (KALV) Latest News & Analysis
Latest News
Quick Summary
KalVista Pharmaceuticals (Nasdaq: KALV) will present new data on sebetralstat at two congresses from May 29–June 1, 2025, focusing on its efficacy in symptom relief and treatment.
Why It Matters
KalVista's upcoming data presentation on sebetralstat could indicate significant advancements in treatment efficacy, potentially impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
KalVista Pharmaceuticals granted inducement options for 14,000 shares to three new employees, effective May 1, 2025, at the closing stock price on that date.
Why It Matters
The grant of stock options to new employees signals KalVista's commitment to attracting talent, which can enhance innovation and drive company growth, potentially impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) will participate in a fireside chat at the Citizens Life Sciences Conference on May 7, 2025, at 11:30 a.m. ET, with a live webcast available on their website.
Why It Matters
KalVista's participation in a major conference could signal upcoming developments or insights that may affect its stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
KalVista: Poised For Rare Disease Transformation
1 month ago
Quick Summary
KalVista's sebetralstat is close to FDA approval for hereditary angioedema. The company has $253.2M in cash, strong financing, and strategic partnerships enhancing its market potential.
Why It Matters
KalVista's nearing FDA approval for sebetralstat enhances its market prospects, backed by strong cash reserves and strategic partnerships, indicating potential for significant returns.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
KalVista Pharmaceuticals licensed Japanese commercialization rights for sebetralstat to Kaken Pharmaceutical, receiving an $11 million upfront payment and potential additional payments up to $11 million.
Why It Matters
KalVista's licensing deal for sebetralstat in Japan with Kaken Pharmaceutical enhances its revenue potential and market reach, signaling growth opportunities that could positively impact its stock value.
Source: Business Wire
Market Sentiment:
Neutral
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
1 month ago
Quick Summary
KalVista Pharmaceuticals (NASDAQ: KALV) will participate in a fireside chat at the Needham Virtual Healthcare Conference on April 7, 2025, at 1:30 p.m. ET. A live webcast will be available.
Why It Matters
KalVista Pharmaceuticals' participation in a major healthcare conference may signal upcoming developments or insights, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About KALV Stock
What is KalVista Pharmaceuticals Inc.'s (KALV) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, KalVista Pharmaceuticals Inc. (KALV) has a median price target of $28.00. The highest price target is $39.00 and the lowest is $18.00.
Is KALV stock a good investment in 2025?
According to current analyst ratings, KALV has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KALV stock?
Wall Street analysts predict KALV stock could reach $28.00 in the next 12 months. This represents a 145.2% increase from the current price of $11.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is KalVista Pharmaceuticals Inc.'s business model?
KalVista Pharmaceuticals operates as a clinical-stage pharmaceutical company, focusing on discovering and developing treatments for diseases with significant unmet medical needs. The company generates revenue through the advancement of its drug candidates, particularly in the niche market of hereditary angioedema, and potentially from future commercialization of its innovative therapies.
What is the highest forecasted price for KALV KalVista Pharmaceuticals Inc.?
The highest price target for KALV is $39.00 from Joseph Schwartz at SVB Leerink, which represents a 241.5% increase from the current price of $11.42.
What is the lowest forecasted price for KALV KalVista Pharmaceuticals Inc.?
The lowest price target for KALV is $18.00 from at , which represents a 57.6% increase from the current price of $11.42.
What is the overall KALV consensus from analysts for KalVista Pharmaceuticals Inc.?
The overall analyst consensus for KALV is bullish. Out of 14 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $28.00.
How accurate are KALV stock price projections?
Stock price projections, including those for KalVista Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 3:32 AM UTC